Novartis taps Vyriad’s viral vectors for in vivo T cell editing
20 Nov 2024 //
FIERCE BIOTECH
Vyriad Partners with Novartis to Develop In Vivo CAR-T Therapies
20 Nov 2024 //
PR NEWSWIRE
Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic
14 Jun 2023 //
PR NEWSWIRE
Vyriad, Inc. Appoints Scott Beck as Chief Operating Officer
13 Sep 2022 //
PRNEWSWIRE
Regeneron-backed oncolytic virus startup scores modest Series B extension
18 May 2022 //
ENDPTS
Vyriad Announces Initiation of Phase 2 Trial in Multiple Cancer Indications
20 Jul 2020 //
GLOBENEWSWIRE